Zoll Foundation Inc.

The ZOLL Foundation operates as a purpose-built 'seed grant' funder for early-career investigators in resuscitation science and acute critical care. Established in 2013 by ZOLL Medical Corporation — the Chelmsford, MA-based maker of defibrillators and resuscitation technology — the foundation maintains close philosophical alignment with its founder's core mission: reducing preventable death from cardiac and cardiopulmonary emergencies.

The foundation's defining preference is for young investigators: researchers within 10 years of their terminal degree who have not yet accumulated significant independent funding. Medical fellows, postdoctoral researchers, instructors, and early assistant professors all qualify. Senior investigators do not. This requirement is non-negotiable and the single most common eligibility barrier applicants face.

The application process is notably accessible compared to peer funders of similar asset size ($25.7M total assets in FY2022). There is no letter of inquiry (LOI) stage and no invitation required — applicants submit a complete proposal through the SmarterSelect portal by March 31 or September 30. The Board of Directors reviews submissions directly; awards are announced approximately 90 days later (late June for the spring cycle, late December for the fall cycle). This biannual rhythm creates two credible application opportunities per calendar year.

Relationship depth matters at the ZOLL Foundation. The Feinstein Institute has received 11 grants totaling $523,080 — the single largest institutional relationship in the grantee database. The University of Pittsburgh has received 4 grants ($189,028) and Massachusetts General Hospital 3 grants ($169,642). These sustained engagements suggest the foundation values productive ongoing research relationships. First-time applicants from institutions with an existing ZOLL Foundation track record benefit from that inherited credibility. For researchers at newer or less-represented institutions, securing a mentor who is a prior ZOLL Foundation grantee is the most effective credibility signal available.

The foundation explicitly positions its grants as 'seed funding' — early capital intended to generate preliminary data enabling investigators to pursue larger NIH or NSF awards. Proposals that articulate this pathway clearly, demonstrating how $45,000-$80,000 in pilot work could underpin a subsequent R01 or R21, align precisely with the foundation's stated theory of change.

First-time applicants should expect a competitive but accessible process: 195 grantees funded across 20 countries and six continents since 2014, with 35 grants awarded in 2024 alone. Geography is not a barrier — research quality and mission alignment to resuscitation and acute critical care are the determining variables.

The ZOLL Foundation's grant program has expanded substantially since its 2014 launch. Total assets grew from $2.2M (FY2014) to a peak of $27.9M in FY2021, driven largely by a $10.2M contribution received in FY2020 — likely an endowment gift timed to ZOLL Medical's acquisition by Asahi Kasei Corporation. Annual grants paid have grown accordingly: $72,000 (FY2014), $753,603 (FY2019), $795,877 (FY2020), $875,696 (FY2021), and $1,452,483 (FY2022). In 2024, the foundation distributed approximately $1.6 million across 35 grants, sustaining its FY2022 pace. Cumulative giving surpassed $9 million to 195 grantees as of September 2025.

Individual grant sizes range from $25,000 to $100,000+. Internal grantee data shows a median grant of approximately $49,112 (average $45,125), drawn from 71 documented grants totaling $3.2 million. Observed awards span from $5,000 (micro-grants to international institutions with limited capacity and professional associations) up to $100,000 for single researcher grants at major academic medical centers — including Stanford University, Brigham and Women's Hospital, and Virginia Commonwealth University. Grants run for two-year periods, beginning in June (spring cycle) or January (fall cycle).

By research area, cardiac arrest and resuscitation science accounts for approximately 75-80% of funded projects: CPR optimization, resuscitation pharmacology (epinephrine, lysophosphatidylcholine, nitroglycerin, lactate), post-arrest neuroprotection, and out-of-hospital cardiac arrest outcomes. The remaining 20-25% spans critical care interventions (sepsis, mechanical ventilation), neonatal resuscitation, traumatic brain injury, organ preservation for transplant, and emergency medicine education. Recent 2025 grants signal growing comfort with multi-omic and CRISPR-based research modalities.

Geographically, New York (14 grantee relationships), Pennsylvania (7), and Massachusetts (5) lead the U.S. states — reflecting the density of academic medical centers, not a geographic preference. International grantees span Denmark, Singapore, Canada, the United Kingdom, France, Belgium, Ethiopia, Greece, Serbia, Japan, and Australia.

Budget exclusions structurally shape award composition: no indirect/overhead costs, no publication fees, most equipment excluded (borrowing encouraged), no conference attendance, and no travel. These exclusions push average awards toward direct research expenditures — reagents, biorepository access, animal model costs, and statistical support — maximizing the dollar-to-research-activity ratio the foundation explicitly seeks.

Among peer foundations in the $20-35M asset range within the Health NTEE category, the ZOLL Foundation stands out in two critical dimensions. First, it operates the most accessible application process — a fully open, biannual competitive cycle requiring no invitation or LOI, giving applicants two opportunities per year compared to peers using invited or closed grant processes. Second, the ZOLL Foundation is the only funder in this peer group with documented global reach spanning 20 countries on six continents; its comparable-asset peers are predominantly U.S.-centric or geographically restricted. The foundation's explicit focus on young investigators within 10 years of their terminal degree is also distinctive, creating a specialized niche for fellowship-trained clinician-researchers and early postdoctoral scientists who would be ineligible for most peer funders in this asset tier.

As of September 2025, the ZOLL Foundation crossed a significant milestone: cumulative giving surpassed $9 million distributed to 195 grantees across 20 countries and six continents. This compares to $6 million reported at the 10-year anniversary in January 2024, indicating approximately $3 million in new grants reaching 45 additional grantees in the intervening 20 months — an accelerating pace.

In 2024, the foundation awarded 35 grants totaling approximately $1.6 million — its highest annual grant count on record, up from approximately 15 grants in 2021. Recent 2025 grantees include researchers at the University of Pennsylvania (Penn CARDIO biorepository, Dr. John Greenwood), Rice University (CRISPR-based cardiac mitochondria research, Mario Escobar Galdamez, PhD), Zhejiang University in collaboration with Massachusetts General Hospital (lactate therapy for post-cardiac arrest brain injury, Dr. Chenghao Wu), and the University of Thessaly in Greece (proteomic evaluation of asphyxial cardiac arrest, Dr. Georgios Mavrovounis). This cohort reflects the foundation's expanding methodological and geographic range.

At the corporate level, ZOLL Medical Corporation appointed Eric Knudsen as its new Chief Executive Officer effective April 1, 2026, succeeding Richard Packer — who serves as Clerk/Director on the ZOLL Foundation board. This is the first major CEO transition at the parent organization since the foundation's 2013 founding. No changes to the foundation's board composition or grant strategy have been publicly announced in connection with this transition.

In May 2026, ZOLL Medical expanded its 'Anything Can Happen. Anyone Can Help.' public awareness campaign to cardiac emergency readiness in youth sports via the RCX Sports Foundation — a separate corporate initiative thematically aligned with the foundation's community education and training grant strand. The foundation's contact email for grant inquiries is grants@zollfoundation.org.

Confirm your 'young investigator' eligibility before investing time. The foundation defines young investigators as researchers within 10 years of their terminal degree. Medical fellows, postdoctoral researchers, instructors, and early assistant professors typically qualify. This is enforced without exception — researchers beyond 10 years post-degree should not apply regardless of research quality or institutional affiliation.

Choose the right cycle based on project readiness. Spring submissions (March 31 deadline) receive award notifications by late June, with projects beginning in June or July. Fall submissions (September 30 deadline) receive notifications by late December, with projects beginning in January. Align your cycle choice with your IRB timeline: IRB approval is not required at submission but is mandatory before any funds are released, so target the cycle that allows you to complete IRB review within 90 days of application.

Treat the mentor requirement strategically, not administratively. The foundation requires a mentor reference letter addressing both the relevance of your research and your personal credentials. The optimal mentor is a prior ZOLL Foundation grantee — researchers at the Feinstein Institute ($523,080 cumulative), University of Pittsburgh ($189,028), or Massachusetts General Hospital ($169,642) offer the strongest institutional signal. If such a mentor is unavailable, choose someone with peer-reviewed publications in resuscitation or acute critical care and make their specific expertise explicit in the letter.

Budget for research activity, not personnel. The foundation's FAQ explicitly states that budgets composed 'nearly exclusively' of salary and fringe benefits are disfavored. Aim to keep salary and fringe below 50% of your total request, and populate the majority with direct research line items: reagents, biorepository access fees, animal model costs, statistical analysis support, or lab consumables. Categorically exclude: indirect/overhead costs, publication fees, most equipment (borrow rather than purchase where possible), conference attendance, and most travel.

Use the language of preliminary data and future larger funding. Every strong proposal articulates the pathway from ZOLL-funded pilot work to a subsequent R01, R21, or equivalent. Use phrases such as 'this grant will generate the preliminary data necessary to support a future NIH R01 application' and specify the downstream funding mechanism you are targeting.

Submit early through SmarterSelect. The portal closes at exactly 11:59 PM ET on the deadline date. Technical difficulties are not grounds for extensions. Submission confirmation emails are sent automatically — retain this record as your timestamp.